<DOC>
	<DOCNO>NCT02029014</DOCNO>
	<brief_summary>The aim study ass efficacy , safety performance LAmbre leave atrial appendage closure system patient non-valvular atrial fibrillation treat Warfarin .</brief_summary>
	<brief_title>Safety Efficacy Study LAmbre LAA Closure Device Treating AF Patients Who Can Take Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age &gt; =18 , CHADS2 score &gt; =1 Patients treat longterm Warfarin Eligible clopidogrel aspirin Provide write informed consent agree comply require followup Need take Warfarin Presence rheumatic , degenerative congenital valvular heart diseases Early stage paroxysmal AF Symptomatic patient carotid artery disease ( carotid stenosis &gt; =50 % ) Heart failure NYHA grade IV Recent 30 day stroke TIA Presence active sepsis endocarditis Cardiac tumor malignancy estimate life expectancy &lt; 2 year Abnormal blood test ; renal disfunction LAA remove heart implant patient Patients plan electrophysiological ablation cardioversion 30 day post implantation LAmbre system Patients history mechanical prosthesis operation Patients pregnant , desire pregnant study Participation trials A known allergy nitinol Patients able complete trial Esophageal ultrasonic exclusion criterion : LAA Ostium &lt; =12mm &gt; =30mm LVEF &lt; 30 % Presence thrombus heart High risk PFO Mitral valve stenosis ( valve area &lt; 2 cm2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>LAmbre</keyword>
</DOC>